BioStock: Fluicell partners with big pharma for 3-D bioprinting project

Single-cell technology developers Fluicell have a good reputation in the biomedical research field for its cutting-edge products aimed at maximising R&D capabilities. Fluicell’s 3-D bioprinter Biopixlar has been the main driver for growth thanks to its increased popularity in the industry, and the company announced last week that it has partnered with a big pharma player to use Biopixlar to create bioprinted heart tissue for safety pharmacological studies.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/09/fluicell-partners-with-big-pharma-for-3-d-bioprinting-project/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se